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A B S T R A C T
Background
The choice of the appropriate perioperative thromboprophylaxis in patients with cancer depends on the relative benefits and harms of
low molecular weight heparin (LMWH) and unfractionated heparin (UFH).
Objectives
To systematically review the evidence for the relative efficacy and safety of LMWH and UFH for perioperative thromboprophylaxis in
patients with cancer.
Search methods
A comprehensive search for trials of anticoagulation in cancer patients including a February 2010 electronic search of: the Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and ISI Web of Science.
Selection criteria
Randomized controlled trials (RCTs) that enrolled cancer patients undergoing a surgical intervention and compared the effects of
LMWH toUFH onmortality, deep venous thrombosis (DVT), pulmonary embolism (PE), bleeding outcomes, and thrombocytopenia.
Data collection and analysis
Two review authors used a standardized form to independently extract in duplicate data on risk of bias, participants, interventions and
outcomes of interest. Where possible, we conducted meta-analyses using the random-effects model.
Main results
Of 8187 identified citations, we included 16 RCTs with 11,847 patients in the meta-analyses, all using preoperative prophylactic
anticoagulation. The overall quality of evidence was moderate. The meta-analysis did not conclusively rule out either a beneficial or
harmful effect of LMWH compared to UFH for the following outcomes: mortality (RR = 0.90; 95% CI 0.73 to 1.10), symptomatic
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DVT (RR = 0.73; 95% CI 0.23 to 2.28), PE (RR = 0.59; 95% CI 0.25 to1.41), minor bleeding (RR = 0.88; 95% CI 0.47 to 1.66)
and major bleeding (RR = 0.84; 95% CI 0.52 to 1.36). LMWH was associated with lower incidence of wound hematoma (RR = 0.60;
95% CI 0.43, 0.84) while UFH was associated with higher incidence of intra-operative transfusion (RR = 1.16; 95% CI 0.69,1.62).
Authors’ conclusions
We found no difference between perioperative thromboprophylaxis with LMWH verus UFH in their effects on mortality and embolic
outcomes in patients with cancer. Further trials are needed to more carefully evaluate the benefits and harms of different heparin
thromboprophylaxis strategies in this population.
P L A I N L A N G U A G E S U M M A R Y
Blood thinners for the prevention of clots in patients with cancer undergoing surgery
Patients with cancer undergoing surgical procedures are at an increased risk of blood clots. The blood thinner administered to prevent
these clots can be either an unfractionated heparin or low molecular weight heparin. These two blood thinners may have different
efficacies and safety profiles. In this systematic review, data from 16 trials found no difference between the two types of agents.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LMWH compared to UFH for perioperative thromboprophylaxis in patients with cancer
Patient or population: pat ients with perioperat ive thromboprophylaxis in pat ients with cancer
Settings: Inpat ient
Intervention: LMWH
Comparison: UFH
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
UFH LMWH
Death
Follow-up: median 2
weeks
35 per 1000 31 per 1000
(26 to 39)
RR 0.9
(0.73 to 1.1)
10483
(9 studies)
⊕⊕⊕©
moderate1
PE
Follow-up: median 2
weeks
7 per 1000 4 per 1000
(2 to 10)
RR 0.59
(0.25 to 1.41)
5900
(13 studies)
⊕⊕⊕©
moderate1
DVT (symptomatic)
Follow-up: median 2
weeks
14 per 1000 10 per 1000
(3 to 32)
RR 0.73
(0.23 to 2.28)
1015
(6 studies)
⊕⊕⊕©
moderate1
Major bleeding
Follow-up: median 2
weeks
49 per 1000 41 per 1000
(25 to 67)
RR 0.84
(0.52 to 1.36)
3441
(7 studies)
⊕⊕⊕©
moderate1
Wound hematoma
Follow-up: median 2
weeks
94 per 1000 56 per 1000
(40 to 79)
RR 0.6
(0.43 to 0.84)
1777
(4 studies)
⊕⊕⊕©
moderate2
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Thrombocytopenia
Follow-up: median 2
weeks
16 per 1000 19 per 1000
(8 to 45)
RR 1.18
(0.49 to 2.81)
1280
(3 studies)
⊕⊕©©
low1,2
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The 95%CI includes both negligible ef fect and appreciable benef it or appreciable harm
2 Possible select ive outcome report ing as few of the 16 included studies report on this outcome
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B A C K G R O U N D
Description of the condition
Patients with cancer undergoing surgical procedures have a higher
risk of venous thromboembolism (VTE) (venous thrombosis
(DVT) and/or pulmonary embolism (PE)) than patients without
cancer (Kakkar 1970; Galus 1997; Rahr 1992). It is estimated that
cancer triples the risk of postoperative DVT (Edmonds 2004).
Moreover, patients with cancer and VTE have an increased risk of
dying than patients with VTE alone or with cancer alone (Levitan
1999;Sorensen 2000). It has been suggested that thromboprophy-
laxis might be less effective in patients with cancer due to the pro-
thrombotic state associated with malignancy (Flordal 1996; Galus
1997)
Description of the intervention
Unfractionated Heparin (UFH), and low-molecular-weight hep-
arins (LMWHs) do not have intrinsic anticoagulant activity but
potentiate the activity of antithrombin III in inhibiting activated
coagulation factors. These agents constitute indirect anticoagu-
lants as their activity is mediated by plasma cofactors. Heparin and
its low molecular weight derivatives are not absorbed orally and
must be administered parenterally (Hirsh 1993).
How the intervention might work
Through their anticoagulant effect, UFH and LMWH reduce the
incidence of both deep venous thrombosisDVTandPE and subse-
quently reduce the incidence of VTE associated mortality (Barritt
1960). At the same time they increase the risk of bleeding which
might be potentiated by the presence of surgical wounds.
Why it is important to do this review
The American College of Chest Physicians (ACCP) recommends
that patients with cancer undergoing surgical interventions re-
ceive thromboprophylaxis “that is appropriate for their current
risk state” which includes the type of surgical intervention (Geerts
2004) Two systematic reviews found that in patients undergoing
colorectal or general surgery respectively, heparins are superior to
no anticoagulation in the prevention of DVT and PE (Boryl 2005;
Mismetti 2001). Mismetti et al. found that among general surgery
patients, LMWH and UFH had similar efficacy and safety irre-
spective of cancer status (Mismetti 2001). However, the authors
did not provide the estimates of the relative effects of the two med-
ications in patients with cancer.
O B J E C T I V E S
To compare the relative efficacy and safety of LMWH and UFH
for perioperative thromboprophylaxis in patients with cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
Patients with cancer planned to undergo a surgical intervention
Types of interventions
Experimental intervention: Low Molecular Weight Heparin
(LMWH)
Comparator intervention: Unfractionated Heparin (UFH)
The protocol should have planned to provide all other co-inter-
ventions similarly in the intervention and comparison group.
Types of outcome measures
The outcome measures did not constitute criteria for including
studies.
Primary outcomes
• All cause mortality
Secondary outcomes
• Symptomatic PE
• Symptomatic DVT
• Asymptomatic DVT
• Bleeding outcomes:
• Major bleeding
• Minor bleeding
• Wound hematoma
• Reoperation for bleeding
• Thrombocytopenia
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Search methods for identification of studies
Electronic searches
The search was part of a comprehensive search for trials of an-
ticoagulation in patients with cancer. We did not use language
restrictions. We electronically searched the following databases:
Cochrane Central Register of ControlledTrials (CENTRAL) (The
Cochrane Library 2010, Issue 1), MEDLINE (1966 to February
2010; accessed via Ovid), EMBASE (1980 to February 2010; ac-
cessed via Ovid), and ISI Web of Science (February 2010). The
search strategies combined terms relating to the anticoagulants,
cancer, and study design. We list the search strategies in Appendix
1.
Searching other resources
We hand-searched the conference proceedings of the American
Society of Clinical Oncology (ASCO) (starting with its first vol-
ume, 1982) and American Society of Hematology (ASH) (start-
ing with its 2003 issue). We reviewed the reference lists of reports
included this review and of other relevant systematic reviews. We
used the related article feature in PubMed to identify additional
articles.
Data collection and analysis
Selection of studies
Two review authors independently screened the title and abstract
of identified citations for potential eligibility. We retrieved the full
text of articles judged potentially eligible by at least one author.
Two review authors then independently screened the full text arti-
cle for eligibility using a standardized form with explicit inclusion
and exclusion criteria (as detailed in the ’Criteria for considering
studies for this review’ section). The two review authors resolved
any disagreements about which articles were eligible by discussion
or by consulting a third review author.
Data extraction and management
We developed and used a standardized data extraction form. Two
review authors independently extracted data from each included
study and resolved their disagreements by discussion. We aimed
to collect data related to:
Participants
• Demographic characteristics (e.g., age, sex)
• Cancer characteristics (e.g., type, location, stage, time since
diagnosis, estimated life expectancy, current cancer treatments,
performance status)
• Description of the surgical procedure
• Co-interventions including radiotherapy, chemotherapy,
and hormonal therapy (type and duration)
• History of VTE
• Use of indwelling central venous catheters
Interventions
• Type of anticoagulant: UFH or LMWH
• Dose: prophylactic versus therapeutic
• Duration of treatment
Outcomes
We attempted to extract both time to event data (for all cause
mortality) and categorical data (for all outcomes). However, none
of the reported time to event data for patients with cancer. For
categorical data, we extracted the reported outcome data necessary
to conduct intention-to-treat analyses. For continuous data we
extracted mean and standard deviation separately for each arm.
We attempted to contact authors for incompletely reported data.
We determined a priori to consider abstracts only if authors sup-
plied us with full reports of their methods and results.
Assessment of risk of bias in included studies
First, we assessed risk of bias at the trial level using the Cochrane
risk of bias tool. Two review authors independently assessed the
risk of bias for each included trial and resolved their disagreements
by discussion. Risk of bias criteria included:
• Adequate sequence generation
• Allocation concealment
• Patient blinding
• Provider blinding
• Data collector blinding
• Outcome assessor blinding
• Analyst blinding
• Percentage of follow-up and whether incomplete outcome
data was addressed
• Whether the trial was free of selective reporting
• Whether the trial was stopped early for benefit
• Whether the analysis followed the intention-to-treat (ITT)
principle
Second, we assessed the quality of evidence at the outcome level us-
ing the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach (Cochrane Handbook).
Measures of treatment effect
We analyzed hazard ratios (HRs) for time to event data, risk ra-
tios (RRs) for categorical data, and standardized mean difference
(SMD) for continuous data.
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Unit of analysis issues
The unit of analysis was the individual participant.
Dealing with missing data
We analyzed the available data assuming that any data that could
be missing were missing at random
Assessment of heterogeneity
Heterogeneity among trials was assessed by visual inspection of
forest plots, estimation of the percentage heterogeneity among tri-
als which cannot be ascribed to sampling variation (I2 statistic)
(Higgins 2003), and by a formal statistical test of the significance
of the heterogeneity (Deeks 2001). If there was evidence of sub-
stantial heterogeneity, the possible reasons for this were investi-
gated and reported.
Assessment of reporting biases
We assessed the potential for publication bias by examining fun-
nel plots corresponding to meta-analysis of the primary outcome.
These plots did not suggest that treatment effects may not have
been sampled from a symmetric distribution, as assumed by the
random effects model, so further meta-analyses were not per-
formed using fixed effects models.
We assessed the potential for selective reporting of outcomes bias
by trying to identify whether the trial was included in a trial reg-
istry, whether a protocol is available, and whether the methods
section provided a list of outcomes. We compared the list of out-
comes from those sources to the outcomes reported on in the pub-
lished paper.
Data synthesis
For categorical data, we calculated the RR separately for each trial
for the incidence of outcomes by treatment arm. We then pooled
the results of the different trials using a random-effects model.
For continuous data, we calculated the SMD separately for each
trial. We then pooled the results of the different trials using a
random-effects model.
We planned to pool clinically similar trials.
Subgroup analysis and investigation of heterogeneity
We planned to explore substantial heterogeneity by conducting
subgroup analyses based on the characteristics of participants
(type, severity and stage of cancer, and whether patients were on
cancer treatment or not). We did not conduct any subgroup anal-
ysis because of the relatively small number of trials and the inclu-
sion of different types of cancer in the same trial.
Sensitivity analysis
We did not conduct any sensitivity analyses.
R E S U L T S
Description of studies
Results of the search
The February 2010 search strategy identified a total of 8187 cita-
tions. In total, the title and abstract screening identified 32 poten-
tially eligible citations. The full text screening of the 44 citations
identified 16 eligible trials.
Included studies
We included 16 trials in this review (Baykal 2001; Bergqvist 1990;
Boncinelli 2001;Dahan 1990; EFS 1988; Enoxacan 1997; Fricker
1988; Gallus 1993; Godwin 1993; Heilmann 1998; Heilmann
1998;McLeod 2001; Onarheim 1986; von Tempelhoff 1997; von
Tempelhoff 2000; Haas 2005; Kakkar 1997). One of these trials
was published as an abstract (Godwin 1993).
Design of studies:
All included studies consisted of RCTs.
Patient characteristics:
Trials were conducted in patients with cancer undergoing the fol-
lowing types of surgery: gynaecological (n = 4) (Baykal 2001;
Heilmann 1998; von Tempelhoff 1997; von Tempelhoff 2000),
abdominal or pelvic (n = 7) (Bergqvist 1990; EFS 1988; Enoxacan
1997; Fricker 1988; Godwin 1993; McLeod 2001; Onarheim
1986), thoracic (n = 1) (Dahan 1990), abdominal or thoracic (n=
1) (Gallus 1993), prostate (n = 1) (Boncinelli 2001), and unspec-
ified (n = 2) (Haas 2005; Kakkar 1997). Mean age of participants
varied from 51 to 71 across included trials.
Interventions:
Types of LMWH studied were: exnoxaparin (n = 2: Baykal 2001;
Enoxacan 1997); dalteparin (n = 3: Bergqvist 1990; Fricker 1988;
Onarheim 1986); nadroxiparin (n = 2: Boncinelli 2001; Dahan
1990); fraxiparin (n = 1: EFS 1988); orgaran (n = 1: Gallus 1993);
normiflo (n = 1: Godwin 1993); certoparin (n = 2: Haas 2005;
Heilmann 1998); and not specified (n = 4: Kakkar 1997; McLeod
2001; von Tempelhoff 1997; von Tempelhoff 2000). All trials
started thromboprophylaxis preoperatively.
Outcomes:
• Nine trials reported on death (Baykal 2001; Bergqvist
1990; Enoxacan 1997; Gallus 1993; Haas 2005; Heilmann
1998; Kakkar 1997; Onarheim 1986; von Tempelhoff 2000).
• Thirteen trials reported on PE (Baykal 2001; Bergqvist
1990; Boncinelli 2001; Dahan 1990; EFS 1988; Enoxacan
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1997; Fricker 1988; Gallus 1993; Godwin 1993; Heilmann
1998; Kakkar 1997; McLeod 2001; Onarheim 1986).
• Six trials reported on symptomatic DVT (Baykal 2001;
Boncinelli 2001; Dahan 1990; Enoxacan 1997; Fricker 1988;
Onarheim 1986).
• Eleven trials reported on asymptomatic DVT (Bergqvist
1990; Dahan 1990; EFS 1988; Enoxacan 1997; Fricker 1988;
Gallus 1993; Godwin 1993; Kakkar 1997; McLeod 2001;
Onarheim 1986; von Tempelhoff 1997).
• Three trials reported on minor bleeding (Enoxacan 1997;
Heilmann 1998; McLeod 2001).
• Seven trials reported on major bleeding (Boncinelli 2001;
Dahan 1990; Enoxacan 1997; Heilmann 1998; Kakkar 1997;
McLeod 2001; Onarheim 1986).
• Four trials reported on wound hematoma (Boncinelli 2001;
Heilmann 1998; Kakkar 1997; Onarheim 1986).
• Two trials reported on re-operation for bleeding (Heilmann
1998; Onarheim 1986).
• Three trials reported on thrombocytopenia (Godwin 1993;
Heilmann 1998; Onarheim 1986).
• None of the trials reported on heparin-induced
thrombocytopenia (HIT).
Excluded studies
We excluded 28 trials from this review. Of these 28 trials, 12 in-
cluded patients with cancer as study subgroups but did not re-
port outcomes on these subgroups. The reason for excluding the
remaining 16 trials were: comparison was between LMWH and
no anticoagulation (n = 5); comparison was between UFH and
no anticoagulation (n = 6); comparison was between 2 weeks of
LMWHand 4 weeks of LMWH (n = 2); comparison of 2 different
doses of heparin (n = 2); and data for the outcome of interest not
available from report or author (n = 1).
Risk of bias in included studies
Figure 1 presents the risk of bias graph while Figure 2 presents
the risk of bias summary associated with the outcomes: death, PE,
DVT and major bleeding.
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation was unclear in seven studies (Bergqvist 1990;
Boncinelli 2001; Dahan 1990; Enoxacan 1997; Fricker 1988;
Godwin 1993; Kakkar 1997; Onarheim 1986; von Tempelhoff
1997) but adequate in the remaining one. Allocation was ad-
equately concealed in six trials (Baykal 2001, Gallus 1993,
Heilmann 1998, McLeod 2001, von Tempelhoff 2000; Haas
2005). Allocation was not reported in 10 trials (Bergqvist 1990;
Boncinelli 2001;Dahan 1990; EFS 1988; Enoxacan 1997; Fricker
1988; Onarheim 1986; von Tempelhoff 1997; Kakkar 1997;
Godwin 1993)
Blinding
All but three trials clearly blinded patients and providers: blinding
status was unclear in one trial (Boncinelli 2001) and was clearly
not done in two (EFS 1988; Fricker 1988). All but four trials
clearly blinded data collectors: blinding status was unclear in two
trials (Boncinelli 2001;McLeod 2001) and was clearly not done in
two (EFS 1988; Fricker 1988). All but seven trials clearly blinded
outcome adjudicators: blinding status was unclear in six trials (
Boncinelli 2001; Enoxacan 1997; Fricker 1988; Gallus 1993;
Godwin 1993; von Tempelhoff 2000) and clearly not done in one
(EFS 1988). Blinding of the data analyst was clearly performed
in one trial (Baykal 2001), and clearly not done in four trials
(Bergqvist 1990; Dahan 1990; EFS 1988; Kakkar 1997); it was
unclear in the rest of trials.
Incomplete outcome data
Follow-up was satisfactory in all the trials with the following per-
centages: 96% in Bergqvist 1990; 99% in EFS 1988; 95% in
Gallus 1993; 89% in Godwin 1993; 91% in Heilmann 1998;
97% in Kakkar 1997; 94% in McLeod 2001 and 100% in the
remaining trials.
Selective reporting
The outcomes listed in the methods section were reported in the
results section for all trials. von Tempelhoff 2000 appears to have
collected data on VTE outcomes but did not report them. It was
unclear whether Dahan 1990 suffered from reporting bias.
Other potential sources of bias
The only trial that was stopped early was Haas 2005 . We judged
the associated risk of bias to be low because stoppage was related
to of insufficient recruitment and not to benefit.
Six trials reported adhering to the ITT principle (Baykal 2001;
Gallus 1993; McLeod 2001; Onarheim 1986; Haas 2005; Kakkar
1997); three trials reported not adhering to the ITT principle (
Bergqvist 1990; Enoxacan 1997; Heilmann 1998); seven trials
did not report on the adherence to the ITT principle ( Boncinelli
2001; Dahan 1990; EFS 1988; Fricker 1988; Godwin 1993; von
Tempelhoff 1997; von Tempelhoff 2000 ).
Effects of interventions
See: Summary of findings for the main comparison LMWH
compared to UFH for perioperative thromboprophylaxis in
patients with cancer
Death
Meta-analysis of nine trials (Baykal 2001; Bergqvist 1990;
Enoxacan 1997;Gallus 1993; Haas 2005;Heilmann 1998; Kakkar
1997;Onarheim1986;vonTempelhoff 2000) assessing 10,483 pa-
tients did not conclusively rule out a mortality reduction with
LMWH compared to UFH (RR = 0.90; 95% CI 0.73 to 1.10):
the percentage of the variability in effect estimates that was due to
heterogeneity between studies rather than sampling error (chance)
was not important (I2 = 0%) (Figure 3). The inverted funnel plot
suggested no publication bias (Figure 4). The quality of evidence
was moderate (Summary of findings for the main comparison).
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Figure 3. Forest plot of comparison: 1 LMWH vs UFH, outcome: 1.1 Death.
Figure 4. Funnel plot of comparison: 1 LMWH vs UFH, outcome: 1.1 Death.
PE
Meta-analysis of thirteen trials (Baykal 2001; Bergqvist 1990;
Boncinelli 2001;Dahan 1990; EFS 1988; Enoxacan 1997; Fricker
1988; Gallus 1993; Godwin 1993;Heilmann 1998; Kakkar 1997;
McLeod 2001; Onarheim 1986) assessing 5,900 patients did not
conclusively rule out a decrease in PE or increase with LMWH
compared to UFH (RR = 0.59; 95% CI 0.25 to 1.41); the per-
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centage of the variability in effect estimates that was due to hetero-
geneity between studies rather than sampling error (chance) was
not important (I2 =17%).
Symptomatic DVT
Meta-analysis of six trials reported on this outcome (Baykal 2001;
Boncinelli 2001; Dahan 1990; Enoxacan 1997; Fricker 1988;
Onarheim1986) assessing 1,015 patients did not conclusively rule
out a symptomatic DVT reduction or increase with LMWH com-
pared to UFH (RR= 0.73; 95% 0.23, 2.28); the percentage of
the variability in effect estimates that was due to heterogeneity be-
tween studies rather than sampling error (chance) was not impor-
tant (I2 =0%). The quality of evidence was moderate (Summary
of findings for the main comparison).
Asymptomatic DVT
Meta-analysis of eleven trials (Bergqvist 1990; Dahan 1990; EFS
1988; Enoxacan 1997; Fricker 1988; Gallus 1993; Godwin 1993;
Kakkar 1997; McLeod 2001; Onarheim 1986; von Tempelhoff
1997) assessing 2333patients showed a reduction in asymptomatic
DVTwith LMWH compared to UFH (RR = 0.8; 95%CI 0.65 to
0.99); the percentage of the variability in effect estimates that was
due to heterogeneity between studies rather than sampling error
(chance) was not important (I2 =2%).
Minor bleeding
Meta-analysis of three trials (Enoxacan 1997; Heilmann 1998;
McLeod 2001) assessing 1,888 patients did not conclusively rule
out a reduction or increase with LMWH compared to UFH (RR
= 0.88; 95% CI 0.47 to 1.66); the percentage of the variability
in effect estimates that was due to heterogeneity between studies
rather than sampling error (chance) represented considerable het-
erogeneity (I2 =75%).
Major bleeding
Meta-analysis of seven trials (Boncinelli 2001; Dahan 1990;
Enoxacan 1997; Heilmann 1998; Kakkar 1997; McLeod 2001;
Onarheim 1986) assessing 3441 patients did not conclusively rule
out a reduction or increase with LMWH compared to UFH (RR
= 0.84; 95% CI 0.52 to 1.36); the percentage of the variability
in effect estimates that was due to heterogeneity between studies
rather than sampling error (chance) represented some heterogene-
ity (I2 = 34%). The quality of evidence was moderate (Summary
of findings for the main comparison).
Would hematoma
Meta-analysis of four trials (Boncinelli 2001;Heilmann 1998;
Kakkar 1997; Onarheim 1986)assessing 1777 patients showed a
reduction with LMWH compared to UFH (RR = 0.6; 95% CI
0.43 to 0.84); the percentage of the variability in effect estimates
that was due to heterogeneity between studies rather than sam-
pling error (chance) was not important (I2 = 0%). The quality
of evidence was moderate (Summary of findings for the main
comparison).
Re-operation for bleeding
Meta-analysis of two trials Heilmann 1998; Onarheim 1986) as-
sessing 376 patients did not conclusively rule out a reduction or
increase with LMWH compared to UFH (RR = 0.70; 95% CI
0.06 to 7.89); the percentage of the variability in effect estimates
that was due to heterogeneity between studies rather than sam-
pling error (chance) represented some heterogeneity (I2 = 40%).
The quality of evidence was low (Summary of findings for the
main comparison).
Intra-operative blood loss
Meta-analysis of four trials (Baykal 2001; Dahan 1990; Gallus
1993; Onarheim 1986) assessing 761 patients found no difference
in effect with LMWH compared to UFH (MD = -0.16; 95% CI
to 0.37 to 5).
Intra-operative transfusion
One trial (Dahan 1990) assessing 84 patients found that the intra-
operative transfusion volume was higher with LMWH compared
to UFH (MD = 74; 95% CI 47 to 102).
Post-operative drain volume
Meta-analysis of two trials (Baykal 2001; EFS 1988) assessing 806
patients found no difference in effect with LMWH compared to
UFH (MD = 27; 95% CI -44 to 98).
Post-operative transfusion
One trial (Dahan 1990) assessing 81 patients found no difference
in effect with LMWH compared to UFH (MD = 79; 95% CI -
54 to 211).
Thrombocytopenia
Meta-analysis of three trials (Godwin 1993; Heilmann 1998;
Onarheim 1986) assessing 1280 patients did not conclusively rule
out a thrombocytopenia reduction or increase with LMWH com-
pared to UFH (RR = 1.18; 95% CI 0.49 to 2.81). The quality of
evidence was low (Summary of findings for themain comparison).
D I S C U S S I O N
Summary of main results
Themeta-analysis of 16 trials with 11,847 patients did not conclu-
sively rule out either beneficial or harmful effect of LMWH com-
pared to UFH relative to mortality, symptomatic DVT, PE, minor
bleeding and major bleeding. LMWH was associated with lower
incidence of wound hematoma (based on four trials) while UFH
was associated with higher incidence of intra-operative transfu-
sion (based on one trial). None of the trials reported on HIT. The
overall quality of evidence was moderate.
Overall completeness and applicability of
evidence
While the absence of a statistically significant difference might
reflect a true absence of effect of LMWHon some VTE outcomes,
this could also be related to insufficient power to detect important
differences between drugs. Another potential explanation is the
relatively low baseline risks for the different outcomes (e.g., the
baseline risk for PE was 0.6% ).
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These trials recruited patients with variety of cancer types and
stages which should increase the applicability of the results.
All included trials started anticoagulant treatment preoperatively.
Consequently, it is not certain how the results apply to anticoagu-
lant treatment started post-operatively. However, a systematic re-
view did not find statistically significant differences in the amount
of blood loss when the first dose of enoxaparin is administered 12
hours before surgery versus post-operatively (Einstein 2007).
Quality of the evidence
The quality of evidence was moderate for mortality, PE, symp-
tomatic DVT, major bleeding and wound hematoma, and was low
for reoperation for bleeding and thrombocytopenia. The overall
quality of evidence was moderate.
Screening patients for DVT may have bias the results of 10 in-
cluded trial. If screening detects thromboses, patients are typi-
cally therapeutically anticoagulated. Some of the patients with
asymptomatic eventsmay have developed symptomatic VTE, had
screening testing not been undertaken and anticoagulant therapy
not been administered. As a result, the number of symptomatic
VTE events in this review, and the differential effect of LMWH
vs. UFH on symptomatic events, may be underestimated.
Potential biases in the review process
Our systematic approach to searching, study selection and data
extraction should have minimized the likelihood of missing rele-
vant trials. We excluded 12 trials that included cancer patients as
subgroups but did not report on their outcome data. The cancer
subgroups in these trials included 3185 participants, compared
to 5822 participants included in the current analysis. This may
introduce bias.
The relatively small number of trials and the inclusion of different
types of malignancies, different types of surgical procedures, dif-
ferent dosing of anticoagulant medications, and different follow-
up periods in the same trials precluded us from conducting the
subgroup analyses to explore effect modifiers.
Agreements and disagreements with other
studies or reviews
A systematic review of thromboprophylaxis in colorectal surgery
found no differences between LMWH and UFH in their effects
on preventing DVT and/or PE (odds ratio = 1.01; 95%CI 0.67 to
1.52)( Boryl 2005). One systematic review compared the effects
of UFH and LMWH thromboprophylaxis on thrombocytopenia
and HIT ( Martel 2005). Most of the included trials were in
orthopedic surgery and only 2 trials prospectively examined HIT
and reported a total of 10 events (all in theUFHgroup). Themeta-
analysis found an odds ratio (OR) of 0.10 (95% CI, 0.01 to 0.82)
forHIT and of 0.47 (95%CI 0.22 to 1.02) for thrombocytopenia,
favoring LMWH. Another meta-analysis comparing therapeutic
doses of UFH and LMWH found no differential effect on HIT
(RR = 1.33; 95% CI 0.77 to 2.30) (Morris 2007).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Given the lack of clear evidence of superiority of one agent over
the other as a result of this imprecision, clinicians should base their
choice on cost and patient preferences using an individualized
decision making process.
Implications for research
Despite the large number of patients enrolled in these trials, there
is still some lack of precision for several critical outcomes. This
is partly because a number of trials assessed surrogate outcome
(asymptomatic DVT) instead of patient important outcomes such
as DVT and PE. Researchers can use these results to plan addi-
tional number of randomized trials to either exclude or confirm
a superiority of one of the 2 agents over the other on patient im-
portant outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Baykal 2001
Methods Randomised double blind trial
Participants 102 patients undergoing surgery for gynaecological malignancy, minimum age of age
40 yrs, mean age 57 years
Interventions Intervention:Enoxaparin 2500 U 2h preoperatively then once daily
Control: UFH 5000 U three times daily
Outcomes Death, DVT, PE, Intraoperative bleeding, Catheter drainage
No screening test was used for diagnosing DVT.
Notes Funded by Eczacibasi-Rhoune Poulenc, Turkey
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk According to author contact: random number table
Allocation concealment (selection bias) Low risk According to author contact: ”sequentially numbered
sealed envelopes“
Blinding of the patients? Low risk According to author contact: yes
Blinding of the providers? Low risk Quote: ”randomised double blind trial“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ”randomised double blind trial“
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Quote: ”the surgical team and those collecting labo-
ratory and clinical data were not informed about the
prophylactic anticoagulation being used“
Blinding of the data analysis? Low risk According to author contact: yes
Incomplete data outcome reported? Low risk Follow up: 100%
Free of selective reporting? Low risk Study not registered. No published protocol. All rel-
evant outcomes listed in the methods section are re-
ported on
Comment: probably yes
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Baykal 2001 (Continued)
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Low risk Comment: probably yes; no inappropriate post ran-
domizations exclusions; 100% follow-up
Bergqvist 1990
Methods Randomised double blind trial
Participants 637 patients with cancer undergoing abdominal surgery (study subgroup); minimum
age of 40 years, mean age of 71 years
Interventions Intervention: Dalteparin 5000 U 10 PM preoperatively then daily x 5-8 days
Control: UFH 5000 U 2h preoperatively then twice daily x 5-8 days
Outcomes DVT, pulmonary embolism, haemorrhage, death
Screening of postoperative DVTwas done for 7 days with radiolabeled fibrinogen uptake
test
Notes Funded by Swedish medical research council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”a total of 1040 patients were randomised“
Comment: unclear
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of the patients? Low risk Quote: ”randomised double blind multicenter trial“
Comment: probably yes
Blinding of the providers? Low risk Quote: ”randomised double blind multicenter trial“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ”randomised double blind multicenter trial“
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Comment: probably yes
Blinding of the data analysis? High risk Comment: probably no
Incomplete data outcome reported? Low risk 96% follow up
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Bergqvist 1990 (Continued)
Free of selective reporting? Low risk Study not registered. No published protocol. All rel-
evant outcomes listed in the methods section are re-
ported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? High risk Quote: ”After randomizations, 38 patients were ex-
cluded; 27 because of cancelled operations, four ow-
ing to withdrawal of consent after randomizations but
before the first injection, and seven for various other
reasons“
Boncinelli 2001
Methods Randomised trial
Participants 50 patient were undergoing prostatectomy for prostate cancer,minimum age of 40 years,
mean age of 60
Interventions Intervention:0.3ml of calcium nadroparin given as single daily SQ injection
Control: UFH given at dose of 5000 units SQ three times daily
In both groups prophylaxis began preoperatively andmaintained throughout the hospital
stay (mean 15 days)
Outcomes DVT, pulmonary embolism, major bleeding, hematoma, in the postoperative period
No scheduled Doppler Ultrasonic surveillance was used
Notes Funding source not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”patients were randomly assigned two groups“
Comment: unclear
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of the patients? Unclear risk Comment: not reported
Blinding of the providers? High risk Quote: ”treatment was continued or interrupted at home under
the decision of the general practitioner“
Comment: probably no as no placebo used
Blinding of the outcome data collectors? High risk Comment: probably no as no placebo used
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Boncinelli 2001 (Continued)
Blinding of the outcome adjudicators? Unclear risk Comment: not reported
Blinding of the data analysis? Unclear risk Comment: not reported
Incomplete data outcome reported? Low risk 100% follow up
Free of selective reporting? Low risk Study not registered. No published protocol. All relevant out-
comes listed in the methods section are reported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Unclear risk Comment: not reported
Dahan 1990
Methods Randomised trial
Participants 100 patients undergoing cancer thoracic surgery; age>18 years,mean age 59 years
Interventions Intervention: Nadroparin 7500 U 12 h preoperatively and 12 h postoperatively until the
2nd postoperative day then 10,000 U once daily on postoperative days 3 to 7
Control: UFH 5000 U 2 h preoperatively and 12 h postoperatively then thrice daily
until the 2nd postoperative day then a dose adjusted to APTT on postoperative days 3
to 7 twice daily
Outcomes DVT, pulmonary embolism, perioperative bleeding and postoperative bleeding
Patients were screened with 125 I-fibrinogen uptake test
Notes Funding source not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”randomized study“
Comment: unclear
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of the patients? Low risk Quote: ”partially double blind“
”first phase conducted double blind“
”second open phase was conducted“
Comment: probably yes
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Dahan 1990 (Continued)
Blinding of the providers? Low risk Quote: ”partially double blind“
”first phase conducted double blind“
”second open phase was conducted“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ”partially double blind“
”first phase conducted double blind“
”second open phase was conducted“
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Quote: ”partially double blind“
”first phase conducted double blind“
”second open phase was conducted“
Comment: probably yes
Blinding of the data analysis? High risk Quote: ”partially double blind“
”first phase conducted double blind“
”second open phase was conducted“
Comment: probably no
Incomplete data outcome reported? Low risk 100% follow up
Free of selective reporting? Unclear risk Study not registered.Nopublished protocol. No outcomes listed
in the methods section
Comment: unclear
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Unclear risk Comment: not reported
EFS 1988
Methods Randomised trial
Participants 704 patients with cancer (study subgroup) scheduled for elective abdominal surgery,
minimum age of 40 years, mean age of 61 years
Interventions Intervention: Fraxiparin 7500 anti-Xa units given subcutaneously
Control: Calcium heparin 5000 units three times daily
Treatment was initiated 2 h before surgery, the second injection was given 8hr after
surgery. Subsequent injections were given every 24 h between 07.00 and 10.00 hours
from the first to the seventh postoperative day
Outcomes DVT, asymptomatic DVT, pulmonary embolism, haemorrhage, death
The patients had radio labelled iodine fibrinogen leg scanning on the day of the surgery
and then daily for seven consecutive days
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EFS 1988 (Continued)
Notes Funded by Sanofi Labaz, GmbH, Pharmzeutische Praparate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”the patient were assigned to treatment with either Frax-
iparin or calcium heparin following randomised schedule “
Comment: yes
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of the patients? High risk Quote: ”the trial was not performed in double blind manner“
Comment: no
Blinding of the providers? High risk Quote: ”the trial was not performed in double blind manner“
Comment: no
Blinding of the outcome data collectors? High risk Quote: ”the trial was not performed in double blind manner“
Comment: no
Blinding of the outcome adjudicators? High risk Quote: ”the trial was not performed in double blind manner“
Comment: probably no
Blinding of the data analysis? High risk Quote: ”the trial was not performed in double blind manner“
Comment: probably no
Incomplete data outcome reported? Unclear risk 99% follow up
Free of selective reporting? Low risk Study not registered. No published protocol. All relevant out-
comes listed in the methods section are reported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Unclear risk Comment: not reported
Enoxacan 1997
Methods Double blind randomised trial
Participants 631 patients undergoing planned curative abdominal or pelvic surgery for cancer (study
subgroup). Minimum age of 40 years old. Mean age of 68.5 years
Interventions Intervention: enoxaparin 40 mg once daily started 2 hours before the surgery
Control: low dose of unfractionated heparin three times daily
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Enoxacan 1997 (Continued)
Outcomes DVT only, asymptomatic DVT, Pulmonary embolism plus DVT, Haemorrhage, death
at 3 months interval
Scheduled bilateral ascending venography was performed 24 hours after the last injection
of the trial substance
Notes Funded by Swedish medical research grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”separate randomisation were made per coun-
try and per hospital to one of two groups“
Comment: unclear
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of the patients? Low risk Quote: ”Double blind randomised trial“
Comment: probably yes
Blinding of the providers? Low risk Quote: ”Double blind randomised trial“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ”Double blind randomised trial“
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Quote: ”the venographic results were evaluated and
agreed on by an independent panel before the code
was broken“
Comment: yes
Blinding of the data analysis? Unclear risk Comment: not reported
Incomplete data outcome reported? Low risk 100% follow up
Comment: probably yes
Free of selective reporting? Low risk Study not registered. No published protocol. All rel-
evant outcomes listed in the methods section are re-
ported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? High risk Quote: ”Efficacy analysis was made on all treated pa-
tients basis as well as on the basis of the evaluable pa-
tients“
”safety analysis was made on all treated patients“
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Enoxacan 1997 (Continued)
”these patients were included in the analysis as they
have been randomised “
Comment: probably no
Fricker 1988
Methods Randomised trial
Participants 80 patients with cancer undergoing surgery for abdominal and pelvic malignancy, min-
imum age of 40 years,mean age of 57.6, 93% female
Interventions Intervention: 2500 anti-Xa Units 2 h before surgery and 12 h after the first injection
and then 5000 anti-Xa Units fragmin injection every morning for 10 days
Control: patients received a 5000 IU of calcium heparin injection 2 h before the surgery
and then at 8-h intervals for the next 10 days
Outcomes DVT, Asymptomatic DVT, pulmonary embolism, Haemorrhage
Radio-labelled fibrinogen tests was used for postoperative screening of DVT
Notes Kabivitrum, France
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”eighty patients undergoing pelvic or abdominal surgery
for cancer were randomised in two groups“
Comment: unclear
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of the patients? High risk Quote: ”we have undertaken a prospective open randomised
trial “
Comment: probably no
Blinding of the providers? High risk Quote: ”we have undertaken a prospective open randomised
trial “
Comment: probably no
Blinding of the outcome data collectors? High risk Quote: ”we have undertaken a prospective open randomised
trial “
Comment: probably no
Blinding of the outcome adjudicators? Unclear risk Comment: not reported
Blinding of the data analysis? Unclear risk Comment: not reported
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Fricker 1988 (Continued)
Incomplete data outcome reported? Unclear risk Follow up 100%
Comment: probably yes
Free of selective reporting? Low risk Study not registered. No published protocol. All relevant out-
comes listed in the methods section are reported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Unclear risk Comment: not reported
Gallus 1993
Methods Double blind randomised trial
Participants 514 patients undergoing abdominal or thoracic cancer surgery, minimum age of 40,
mean age of 65 years
Interventions Intervention: Orgaran 750 U 1-2h preoperatively then at 12 h intervals x 6 days
Control: UFH 5000 U 1-2h preoperatively then at 12h intervals x 6 days
Outcomes DVT, pulmonary embolism, Haemorrhage, death
Radio -labelled fibrinogen testswas used for screening of postoperativeDVTevery second
day on the week days
Notes Funded by Organon International. Oss. The Netherlands.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”using predetermined randomisation se-
quences for each trial center“
Comment: yes
Allocation concealment (selection bias) Low risk Quote: ” coded ampoules of Orgaran and Na heparin
were supplied by Organon International B.V and dis-
pensed in numbered boxes by hospital pharmacies us-
ing predetermined randomisation sequences for each
trial center“
Comment: yes
Blinding of the patients? Low risk Quote: ”double blind multicenter trial“
Comment: probably yes
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Gallus 1993 (Continued)
Blinding of the providers? Low risk Quote: ”double blind multicenter trial“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ”double blind multicenter trial“
Comment: probably yes
Blinding of the outcome adjudicators? Unclear risk Comment: not reported
Blinding of the data analysis? Unclear risk Comment: not reported
Incomplete data outcome reported? Low risk 95% follow up
Free of selective reporting? Low risk Study not registered. No published protocol. All rel-
evant outcomes listed in the methods section are re-
ported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Low risk Quote: ”intent to treat analysis showed statistically
non-significant toward trend towards less VT during
Orgaran prophylaxis“
Comment: probably yes
Godwin 1993
Methods Double blind randomised trial
Participants 904 patients undergoing abdominal or pelvic cancer surgery
Interventions Intervention: RDH (Normiflo) 50 U 2h preoperatively and then 90 U once or twice
daily
Control: UFH 5000 U 2h preoperatively and then 5000 U twice daily
Outcomes DVT, pulmonary embolism, bleeding, death
Patients were screened for DVT preoperatively by non -invasive venous tests, either
impedence plethysmography or duplex ultra sound scan
Notes KabiVitrum funded the study
Risk of bias
Bias Authors’ judgement Support for judgement
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Godwin 1993 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: ”a total of 904 patients were randomised into
three groups“
Comment: unclear
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of the patients? Low risk Quote: ”double blind randomised trial“
Comment: probably yes
Blinding of the providers? Low risk Quote: ”double blind randomised trial“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ”double blind randomised trial“
Comment: probably yes
Blinding of the outcome adjudicators? Unclear risk Comment: not reported
Blinding of the data analysis? Unclear risk Comment: not reported
Incomplete data outcome reported? Low risk 89% follow up
Free of selective reporting? Low risk Study not registered. No published protocol. All rel-
evant outcomes listed in the methods section are re-
ported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Unclear risk Comment: not reported
Haas 2005
Methods Double blind randomised control trial
Participants 6124 patient with cancer undergoing cancer surgery, minimum age of 40 years, mean
age 62
Interventions Intervention: LMWH Certoparin 3000 anti- Xa IU, subcutaneously, once-daily
Control: UFH (5000 IU), administered subcutaneously three-times daily
Outcomes Death, pulmonary embolism, bleeding complications (Wound hematoma; Post-opera-
tive wound bleeding; Gastric bleeding)
Notes Funded by: Novartis Pharma GmbH, Nürnberg, Germany
Risk of bias
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Haas 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Patients were randomised to one of
two treatment groups using a centralised com-
puter generated randomizations list“
Comment: yes
Allocation concealment (selection bias) Low risk Quote: ”Patients were randomised to one of
two treatment groups using a centralised com-
puter generated randomizations list “
Comment: yes
Blinding of the patients? Low risk Quote: ” double-blind clinical trial“; ”Placebo
injections were given to Certoparin patients to
conform to the double blind trial design“
Comment: probably yes
Blinding of the providers? Low risk Quote: ” double-blind clinical trial“; ”Placebo
injections were given to Certoparin patients to
conform to the double blind trial design“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ” double-blind clinical trial“; ”Placebo
injections were given to Certoparin patients to
conform to the double blind trial design“
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Quote: ” double-blind clinical trial“; ”Placebo
injections were given to Certoparin patients to
conform to the double blind trial design“
Comment: probably yes
Blinding of the data analysis? Unclear risk Quote: ”The statistical analysis was performed
by an independent statistician and under the
guidance of the Steering Committee“
Comment: unclear
Incomplete data outcome reported? Low risk 100% f/u for mortality; 70% f/u for fatal PE
Free of selective reporting? Unclear risk Study not registered. No published protocol.
All relevant outcomes listed in the methods
section are reported on
Comment: probably yes
Free of other bias? Low risk Quote: ”the decision was taken to end the
study prematurely as the study would not be
sufficiently power- ed to show superiority of
Certoparin over UFH“
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Haas 2005 (Continued)
Comment: probably no
Intention to treatment analysis? Low risk Quote: ”The analyses included all randomised
patients (intention-to-treat)“
Comment: yes
Heilmann 1998
Methods Double blind randomised trial
Participants 358 patients undergoing breast and pelvic cancer surgery, minimum age of 40
Interventions Intervention: Certoparin 3000 U 2-5h preoperatively then once daily x 7 days
Control: UFH 5000 U 2-5h preoperatively then thrice daily x 7 days
Outcomes DVT, pulmonary embolism, major bleeding, minor bleeding, wound hematoma, reop-
eration for hematoma
Patient underwent scheduled impedence plethysmography on postoperative days 1, 3,
5, 7, and 10
Notes Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”patients were randomly allocated to the two
treatment groups“
Comment: probably yes, particularly given themethod
of allocation concealment used
Allocation concealment (selection bias) Low risk Quote: ” prefilled ampoules, prepared by NOVARTIS
GmbH,Nuneberg were identical in appearance. Boxes
were labelled with trial code number and contained
sufficient drug for 10 days“
Comment: yes
Blinding of the patients? Low risk Quote: ”double blind randomised trial“
Comment: probably yes
Blinding of the providers? Low risk Quote: ”double blind randomised trial“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ”double blind randomised trial“
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Quote: ”double blind randomised trial“
Comment: probably yes
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Heilmann 1998 (Continued)
Blinding of the data analysis? Unclear risk Comment: not reported
Incomplete data outcome reported? Low risk 91% follow up
Free of selective reporting? Low risk Study not registered. No published protocol. All rel-
evant outcomes listed in the methods section are re-
ported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? High risk Quote: ”a total of 358 patients were entered into the
trial of whom 34 (9.5%) were exclude after randomisa-
tion because written informed consent was withdrawn
by the patient or medication errors such as late or no
injection of heparin or discontinuation of prophylaxis
before seventh postoperative day“
Comment: no
Kakkar 1997
Methods Double blind randomised trial
Participants 706 patient with an underlying malignancy (out of a total of 1351 patients (52%))
undergoing surgery, minimum age of 40 years, mean age of 59.6
Interventions Intervention: LMWH 1750 anti-Xa IU administered subcutaneously (SC) once daily
with a second injection of saline (placebo) 12 hours later
Control: UFH 5000 IU SC every 12 hours
Treatment commenced 2 hours prior to surgery followed by a second injection 8 hours
postoperatively and continued for at least 5 days (longer if the patient was still confined
to bed)
Outcomes Death, DVT, PE, Bleeding complications, Wound hematoma, wound complications
(hematoma; oozing; bruising), Injection site complications (Hemorrhage; Hypersensi-
tivity ;Inflammation ;Pain)
Scheduled radioactive fibrinogen uptake test was done daily for DVT screening
Notes Funded by Knoll AG, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Patients were randomly allocated“
Comment: unclear
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Kakkar 1997 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of the patients? Low risk Quote: ” double-blind multicenter trial “
Comment: probably yes
Blinding of the providers? Low risk Quote: ” double-blind multicenter trial “
Comment: probably yes
Blinding of the outcome data collectors? Unclear risk Quote: ” double-blind multicenter trial “
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Quote: ”The final diagnosis of DVT or PE was based
on the assessment of a blinded expert committee“
Comment: probably yes
Blinding of the data analysis? High risk Comment: not reported; probably not
Incomplete data outcome reported? Low risk Quote: ”The number of patients who could not be
analyzed for efficacy was similar in the two groups: 24
(3.6%) with LMWH and 16 (2.4%) with UFH.“
Comment: most likely relate to the outcome of asymp-
tomatic DVT
Free of selective reporting? Low risk Study not registered. No published protocol. All rel-
evant outcomes listed in the methods section are re-
ported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Low risk Quote: ”The study was analysed in accordance with
the intention-to-treat principle“
Cooment: yes
McLeod 2001
Methods Randomised double blind trial
Participants 475 patients with cancer undergoing colorectal cancer surgery, mean age of 51 years
Interventions Intervention: 40mg of LMWH (100 antifactor Xa units per milligram) subcutaneously
once daily in the morning plus two placebo injections
Control: 5,000 units of calcium heparin every 8 hours
Prophylaxis was initiated 2h before the surgery and one further injection (heparin or
placebo) at 8pm at the day of the surgery. Thereafter, patients received three injections
daily for up to 10 days
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McLeod 2001 (Continued)
Outcomes DVT, asymptomatic DVT, pulmonary embolism, major bleeding and minor bleeding
Scheduled bilateral ascending contrast venography was done on or before post-operative
day 9
Notes Funded by Rhone-Poulenc Rorer Canada Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”patients were randomised to receive either cal-
cium heparin or enoxaparin“
Comment: probably yes, particularly given the
method of allocation concealment used
Allocation concealment (selection bias) Low risk Quote: ”a central computer -generated randomisation
scheme inblocks of fourwas used to prepare numbered
kits of study medication that were provided to the
pharmacy departments of study centers“
”the study injections were prepared as 0.2-ml
preloaded, consecutively numbered syringes“
Comment: yes
Blinding of the patients? Low risk Quote: ”randomised double blind trial“
Comment: probably yes
Blinding of the providers? Low risk Quote: ”randomised double blind trial“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ”randomised double blind trial“
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Quote: ”all the venograms and other imaging studies
for venous thromboembolism were reviewed by cen-
tral adjudication committee which was unaware of the
treatment allocation and used detailed coding form
with prespecified criteria“
Comment: yes
Blinding of the data analysis? Unclear risk Comment: not reported
Incomplete data outcome reported? Low risk Follow up 94%
Comment: probably yes
Free of selective reporting? Low risk Study not registered. No published protocol. All rel-
evant outcomes listed in the methods section are re-
ported on
Comment: probably yes
33Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McLeod 2001 (Continued)
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Low risk Quote: ”all randomised patients, except those who did
not fulfil the entry criteria, were included in the anal-
ysis of blood loss and bleeding events“
Comment: probably yes
Onarheim 1986
Methods Randomised double blind trial
Participants 52 patients undergoing surgery for abdominal malignancy, minimum age of 40 years,
mean age of 70.35 years
Interventions Intervention: Dalteparin 5000 U 2h preoperatively
then once daily x 6 days
Control: Heparin Kabi 2165 5000 U
2h preoperatively then twice daily x 6 days
Outcomes Death, DVT, pulmonary embolism, major bleeding, wound hematoma
thrombocytopenia
Radioactive firbrinogen uptake test was used for DVT screening and was performed
preoperatively and then daily or every second day for at least 7 postoperative days
Notes Funded by Kabivitrum
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”patients were randomly allocated to receive
conventional heparin (heparin group) or LMWH
KABI 2165 (LMWH group)“
Comment: unclear
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of the patients? Low risk Quote: ”double blind trial“
”A placebo injection was given each evening, in order
in order to keep the study completely blind“
Comment: probably yes
Blinding of the providers? Low risk Quote: ”double blind trial“
”A placebo injection was given each evening, in order
in order to keep the study completely blind“
Comment: probably yes
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Onarheim 1986 (Continued)
Blinding of the outcome data collectors? Low risk Quote: ”double blind trial“
”A placebo injection was given each evening, in order
in order to keep the study completely blind“
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Quote: ”double blind trial“
”A placebo injection was given each evening, in order
in order to keep the study completely blind“
Comment: probably yes
Blinding of the data analysis? Unclear risk Comment: not reported
Incomplete data outcome reported? Low risk Follow up: 100%
Free of selective reporting? Low risk Study not registered. No published protocol. All rel-
evant outcomes listed in the methods section are re-
ported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Low risk Quote: ”the data collected from52patientswere there-
fore uniformly analysed on an “intention to treat” ba-
sis“
Comment: probably yes
von Tempelhoff 1997
Methods Randomised trial
Participants 60 patient with ovarian cancer undergoing surgery and chemotherapy, mean age 56.7
Interventions Intervention: 3000anti-Xa units/day of LMWH plus 2 placebo injections
Control: 5000 IU/day of UFH three times a day.
Prohylaxis begins was begun 2 h before operation and continued until the 7th postop-
erative day
Outcomes DVT, asymptomatic DVT.
Impedance plethysmography was used for DVT screening on days 1, 3, 5, 7 and10
Notes Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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von Tempelhoff 1997 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: ”all patients were eligible for surgery and randomised to
receive either daily LMWH or UFH“
Comment: unclear
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of the patients? Low risk Quote: ”All 60 patients were randomised in double blind man-
ner to receive either LMWH or UFH“
Comment: probably yes
Blinding of the providers? Low risk Quote: ”All 60 patients were randomised in double blind man-
ner to receive either LMWH or UFH“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ”All 60 patients were randomised in double blind man-
ner to receive either LMWH or UFH“
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Quote: ”All 60 patients were randomised in double blind man-
ner to receive either LMWH or UFH“
Comment: probably yes
Blinding of the data analysis? Unclear risk Comment: not reported
Incomplete data outcome reported? Low risk follow up 100%
Comment: probably yes
Free of selective reporting? Low risk Study not registered. No published protocol. All relevant out-
comes listed in the methods section are reported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention to treatment analysis? Unclear risk Comment: not reported
von Tempelhoff 2000
Methods Randomised double blind trial
Participants 350 patients with either histologically confirmed carcinoma of the breast, endometrium,
vulva or vagina, or with suspected ovarian malignancy were included, minimum age of
40, mean age of 61 years
Interventions Intervention: LMW heparin given at a dose of 3,000 anti-Xa units subcutaneously once
daily in combination with 2 placebo injections (0.9% NaCl)
Control: the patient were assigned to thrombosis prophylaxis with UF heparin received
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von Tempelhoff 2000 (Continued)
5,000 IU subcutaneously three times daily
Intial injection was given 2h before the surgery always contained active drug. In both
treatment arms study medication was given at 8h interval until 7th postoperative day
Outcomes Death. The one relevant outcome listed in the methods section is reported on
Notes Funded by Novartis Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”patient who randomly received LMW hep-
arin (certoparin) compared to patients given UF
heparin for thrombosis prophylaxis during primary
surgery“
Comment: probably yes, particularly given the
method of allocation concealment used
Allocation concealment (selection bias) Low risk Quote: ”the boxes and ampoules of both heparins were
labelled with a trial code number but were identical
in appearance so neither the patient nor the staff were
aware of the kind of heparin administered“
Comment: yes
Blinding of the patients? Low risk Quote: ”Randomised double blind trial“
Comment: probably yes
Blinding of the providers? Low risk Quote: ”Randomised double blind trial“
Comment: probably yes
Blinding of the outcome data collectors? Low risk Quote: ”Randomised double blind trial“
Comment: probably yes
Blinding of the outcome adjudicators? Unclear risk Quote: ”Randomised double blind trial“
Comment: probably yes
Blinding of the data analysis? Unclear risk Comment: not reported
Incomplete data outcome reported? Low risk follow up 100%
Comment: probably yes
Free of selective reporting? High risk Study appears to have collected data onVTEoutcomes
but do not report them
Comment: probably no
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
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von Tempelhoff 2000 (Continued)
Intention to treatment analysis? High risk Quote: ”patients were not randomised according to
intention to treat principle“
Comment: probably no
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arbeit 1981 Comparison is not of interest: UFH vs no anticoagulant
Azorin 1997 Comparsion is not of interest: LMWH vs no anticoagulant
Bergqvist 1986 Study included patients with cancer as a subgroup for which outcome data were not available
Bergqvist 1988 Study included patients with cancer as a subgroup for which outcome data were not available
Bergqvist 2002 Comparsion is not of interest: LMWH (4weeks) vs LMWH (1week)
Boneu 1993 Study included patients with cancer as a subgroup for which outcome data were not available
Borstad 1988 Study included patients with cancer as a subgroup for which outcome data were not available
Borstad 1992 Study included patients with cancer as a subgroup for which outcome data were not available
Bricchi 1991 Comparisonn is not of interest: UFH vs no anticoagulant
Cade 1983 Comparison is not of interest: the study compared the efficacy of a higher dose of heparin (7500 U twice
daily) with the commonly used dose of 5000 U
Caprini 2003 Comparsion is not of interest: LMWH vs no anticoagulant
Clark-Pearson 1990 a Comparsion is not of interest: UFH vs no anticoagulant
Clark-Pearson 1990 b Comparison is not of interest: comparison between two doses of UFH
Clarke-Pearson 1983 Comparsion is not of interest: UFH vs no anticoagulant
Dickinson 1998 Comparsion is not of interest: LMWH vs no anticoagulant
Gondret 1995 Comparsion is not of interest: LMWH vs no anticoagulant
Ho 1999 Comparsion is not interest: LMWH vs no anticoagulant
Kakkar 1989 Study included patients with cancer as a subgroup for which outcome data were not available
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(Continued)
Kakkar 1985 Study included patients with cancer as a subgroup for which outcome data were not available
Liezorovicz A 1991 Study included patients with cancer as a subgroup for which outcome data were not available
Limmer 1994 Study included patients with cancer as a subgroup for which outcome data were not available
Macdonald 2003 Study included patients with cancer as a subgroup for which outcome data were not available
Marassi 1993 Comparsion is not interest: LMWH vs no anticoagulant
Nurmohamed 1995 Data for the outcome of interest not available from report or author
Rasmussen 2003 Comparsion is not of interest: LMWH (4weeks) vs LMWH (1week)
Samama 1988 Study included patients with cancer as a subgroup for which outcome data were not available
Shukla 2008 Comparsion is not interest: LMWH vs no anticoagulant
Ward 1998 Study included patients with cancer as a subgroup for which outcome data were not available
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D A T A A N D A N A L Y S E S
Comparison 1. LMWH vs UFH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 9 10483 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.73, 1.10]
2 PE 13 5900 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.25, 1.41]
3 DVT (symptomatic) 6 1015 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.23, 2.28]
4 DVT (asymptomatic) 11 5333 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.65, 0.99]
5 Minor bleeding 3 1888 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.47, 1.66]
6 Major bleeding 7 3441 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.52, 1.36]
7 Wound hematoma 4 1777 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.43, 0.84]
8 Reoperation for bleeding 2 376 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.06, 7.89]
9 Intra-operative blood loss 4 761 Mean Difference (IV, Random, 95% CI) -16.01 [-36.82, 4.
80]
10 Intra-operative transfusion 1 84 Mean Difference (IV, Random, 95% CI) 74.30 [47.01, 101.
59]
11 Postoperative drain volume 2 806 Mean Difference (IV, Random, 95% CI) 27.26 [-43.89, 98.
41]
12 Post-operative transfusion 1 81 Mean Difference (IV, Random, 95% CI) 78.6 [-53.58, 210.
78]
13 Thrombocytopenia 3 1280 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.49, 2.81]
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Analysis 1.1. Comparison 1 LMWH vs UFH, Outcome 1 Death.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 1 Death
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Baykal 2001 0/47 0/55 Not estimable
Bergqvist 1990 5/311 8/326 3.4 % 0.66 [ 0.22, 1.98 ]
Enoxacan 1997 11/556 14/560 6.9 % 0.79 [ 0.36, 1.73 ]
Gallus 1993 22/241 16/249 11.0 % 1.42 [ 0.76, 2.64 ]
Haas 2005 94/3091 98/3033 54.3 % 0.94 [ 0.71, 1.24 ]
Heilmann 1998 5/160 3/164 2.1 % 1.71 [ 0.42, 7.03 ]
Kakkar 1997 3/672 5/679 2.1 % 0.61 [ 0.15, 2.53 ]
Onarheim 1986 0/25 0/27 Not estimable
von Tempelhoff 2000 24/140 38/147 20.3 % 0.66 [ 0.42, 1.05 ]
Total (95% CI) 5243 5240 100.0 % 0.90 [ 0.73, 1.10 ]
Total events: 164 (LMWH), 182 (UFH)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.42, df = 6 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours UFH
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Analysis 1.2. Comparison 1 LMWH vs UFH, Outcome 2 PE.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 2 PE
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Baykal 2001 0/47 0/55 Not estimable
Bergqvist 1990 0/311 2/326 7.4 % 0.21 [ 0.01, 4.35 ]
Boncinelli 2001 0/25 0/25 Not estimable
Dahan 1990 0/50 0/50 Not estimable
EFS 1988 0/355 0/349 Not estimable
Enoxacan 1997 0/312 2/319 7.4 % 0.20 [ 0.01, 4.24 ]
Fricker 1988 0/40 5/40 8.2 % 0.09 [ 0.01, 1.59 ]
Gallus 1993 2/241 2/249 15.6 % 1.03 [ 0.15, 7.28 ]
Godwin 1993 1/595 3/309 12.3 % 0.17 [ 0.02, 1.66 ]
Heilmann 1998 7/160 4/164 30.1 % 1.79 [ 0.54, 6.01 ]
Kakkar 1997 1/672 3/679 12.3 % 0.34 [ 0.04, 3.23 ]
McLeod 2001 1/241 0/234 6.7 % 2.91 [ 0.12, 71.15 ]
Onarheim 1986 0/25 0/27 Not estimable
Total (95% CI) 3074 2826 100.0 % 0.59 [ 0.25, 1.41 ]
Total events: 12 (LMWH), 21 (UFH)
Heterogeneity: Tau2 = 0.28; Chi2 = 8.48, df = 7 (P = 0.29); I2 =17%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 LMWH vs UFH, Outcome 3 DVT (symptomatic).
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 3 DVT (symptomatic)
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Baykal 2001 0/47 0/55 Not estimable
Boncinelli 2001 0/25 0/25 Not estimable
Dahan 1990 0/50 0/50 Not estimable
Enoxacan 1997 4/312 6/319 82.6 % 0.68 [ 0.19, 2.39 ]
Fricker 1988 1/40 1/40 17.4 % 1.00 [ 0.06, 15.44 ]
Onarheim 1986 0/25 0/27 Not estimable
Total (95% CI) 499 516 100.0 % 0.73 [ 0.23, 2.28 ]
Total events: 5 (LMWH), 7 (UFH)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 LMWH vs UFH, Outcome 4 DVT (asymptomatic).
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 4 DVT (asymptomatic)
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bergqvist 1990 22/311 34/326 15.7 % 0.68 [ 0.41, 1.13 ]
Dahan 1990 0/50 0/50 Not estimable
EFS 1988 15/355 19/349 9.6 % 0.78 [ 0.40, 1.50 ]
Enoxacan 1997 41/312 52/319 28.0 % 0.81 [ 0.55, 1.18 ]
Fricker 1988 2/40 0/40 0.5 % 5.00 [ 0.25, 100.97 ]
Gallus 1993 19/241 28/249 13.4 % 0.70 [ 0.40, 1.22 ]
Godwin 1993 0/595 3/309 0.5 % 0.07 [ 0.00, 1.43 ]
Kakkar 1997 30/672 28/679 16.2 % 1.08 [ 0.65, 1.79 ]
McLeod 2001 20/164 27/160 14.4 % 0.72 [ 0.42, 1.23 ]
Onarheim 1986 2/25 2/27 1.2 % 1.08 [ 0.16, 7.10 ]
von Tempelhoff 1997 4/28 0/32 0.5 % 10.24 [ 0.58, 182.23 ]
Total (95% CI) 2793 2540 100.0 % 0.80 [ 0.65, 0.99 ]
Total events: 155 (LMWH), 193 (UFH)
Heterogeneity: Tau2 = 0.00; Chi2 = 9.18, df = 9 (P = 0.42); I2 =2%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 LMWH vs UFH, Outcome 5 Minor bleeding.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 5 Minor bleeding
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Enoxacan 1997 81/556 88/560 42.0 % 0.93 [ 0.70, 1.22 ]
Heilmann 1998 12/160 28/164 31.2 % 0.44 [ 0.23, 0.83 ]
McLeod 2001 17/229 9/219 26.8 % 1.81 [ 0.82, 3.97 ]
Total (95% CI) 945 943 100.0 % 0.88 [ 0.47, 1.66 ]
Total events: 110 (LMWH), 125 (UFH)
Heterogeneity: Tau2 = 0.23; Chi2 = 7.87, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 LMWH vs UFH, Outcome 6 Major bleeding.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 6 Major bleeding
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boncinelli 2001 0/25 1/25 2.2 % 0.33 [ 0.01, 7.81 ]
Dahan 1990 2/50 3/50 6.6 % 0.67 [ 0.12, 3.82 ]
Enoxacan 1997 23/556 16/560 27.0 % 1.45 [ 0.77, 2.71 ]
Heilmann 1998 27/160 47/164 36.2 % 0.59 [ 0.39, 0.90 ]
Kakkar 1997 9/672 15/679 20.4 % 0.61 [ 0.27, 1.38 ]
McLeod 2001 5/229 1/219 4.6 % 4.78 [ 0.56, 40.60 ]
Onarheim 1986 1/25 1/27 2.9 % 1.08 [ 0.07, 16.36 ]
Total (95% CI) 1717 1724 100.0 % 0.84 [ 0.52, 1.36 ]
Total events: 67 (LMWH), 84 (UFH)
Heterogeneity: Tau2 = 0.12; Chi2 = 9.03, df = 6 (P = 0.17); I2 =34%
Test for overall effect: Z = 0.70 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 LMWH vs UFH, Outcome 7 Wound hematoma.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 7 Wound hematoma
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boncinelli 2001 2/25 2/25 3.2 % 1.00 [ 0.15, 6.55 ]
Heilmann 1998 18/160 29/164 37.8 % 0.64 [ 0.37, 1.10 ]
Kakkar 1997 29/672 52/679 57.9 % 0.56 [ 0.36, 0.88 ]
Onarheim 1986 0/25 1/27 1.1 % 0.36 [ 0.02, 8.43 ]
Total (95% CI) 882 895 100.0 % 0.60 [ 0.43, 0.84 ]
Total events: 49 (LMWH), 84 (UFH)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 LMWH vs UFH, Outcome 8 Reoperation for bleeding.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 8 Reoperation for bleeding
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heilmann 1998 1/160 4/164 60.5 % 0.26 [ 0.03, 2.27 ]
Onarheim 1986 1/25 0/27 39.5 % 3.23 [ 0.14, 75.83 ]
Total (95% CI) 185 191 100.0 % 0.70 [ 0.06, 7.89 ]
Total events: 2 (LMWH), 4 (UFH)
Heterogeneity: Tau2 = 1.30; Chi2 = 1.68, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 LMWH vs UFH, Outcome 9 Intra-operative blood loss.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 9 Intra-operative blood loss
Study or subgroup Favours LMWH UFH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Baykal 2001 47 915.5 (399.9) 55 798.4 (535.3) 1.3 % 117.10 [ -64.79, 298.99 ]
Dahan 1990 48 290.8 (48.2) 46 307.5 (56.7) 95.3 % -16.70 [ -38.02, 4.62 ]
Gallus 1993 257 573 (644) 256 615 (714) 3.1 % -42.00 [ -159.68, 75.68 ]
Onarheim 1986 25 528 (479) 27 646 (956) 0.3 % -118.00 [ -524.55, 288.55 ]
Total (95% CI) 377 384 100.0 % -16.01 [ -36.82, 4.80 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.49, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 LMWH vs UFH, Outcome 10 Intra-operative transfusion.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 10 Intra-operative transfusion
Study or subgroup LMWH UFH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Dahan 1990 41 398.7 (68.7) 43 324.4 (58.2) 100.0 % 74.30 [ 47.01, 101.59 ]
Total (95% CI) 41 43 100.0 % 74.30 [ 47.01, 101.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.34 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 LMWH vs UFH, Outcome 11 Postoperative drain volume.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 11 Postoperative drain volume
Study or subgroup LMWH UFH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Baykal 2001 47 836.8 (533.2) 55 723.2 (543.7) 11.5 % 113.60 [ -95.88, 323.08 ]
EFS 1988 355 478 (522) 349 462 (502) 88.5 % 16.00 [ -59.65, 91.65 ]
Total (95% CI) 402 404 100.0 % 27.26 [ -43.89, 98.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 LMWH vs UFH, Outcome 12 Post-operative transfusion.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 12 Post-operative transfusion
Study or subgroup LMWH UFH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Dahan 1990 40 234.2 (425) 41 155.6 (36.6) 100.0 % 78.60 [ -53.58, 210.78 ]
Total (95% CI) 40 41 100.0 % 78.60 [ -53.58, 210.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 LMWH vs UFH, Outcome 13 Thrombocytopenia.
Review: Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
Comparison: 1 LMWH vs UFH
Outcome: 13 Thrombocytopenia
Study or subgroup LMWH UFH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Godwin 1993 7/595 4/309 51.0 % 0.91 [ 0.27, 3.08 ]
Heilmann 1998 6/160 4/164 49.0 % 1.54 [ 0.44, 5.35 ]
Onarheim 1986 0/25 0/27 Not estimable
Total (95% CI) 780 500 100.0 % 1.18 [ 0.49, 2.81 ]
Total events: 13 (LMWH), 8 (UFH)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search strategies for the electronic databases
Database Strategy
MEDLINE #1 Heparin/
#2 Heparin.tw
#3 Heparin, Low-Molecular-Weight/
#4 (LMWH OR low molecular weight heparin OR nadroparin OR
fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin
OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logi-
parin OR innohep OR certoparin OR sandoparin OR reviparin OR
clivarin OR danaproid OR orgaran).tw
#5 1 OR 2 OR 3 OR 4
#6 Coumarins/
#7 Warfarin/
#8 (warfarin OR coumadin OR acenocumarol OR phenprocumon
OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K an-
tagonist OR VKA).tw
#9 6 OR 7 OR 8
#10 (fondaparinux OR Arixtra).tw
#11 (ximelagatran OR Exanta).tw
#12 (Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban).
tw.
#13 5 OR 9 OR 10 OR 11 OR 12
#14 Neoplasms/
#15 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR
adenocarcinoma OR tumour OR tumor).tw
#16 14 OR 15
#17 clinical trial.pt. OR random:.tw. OR tu.xs.
#18 animals/ NOT human/
#19 17 NOT 18
#20 13 AND 16 AND 19
EMBASE #1 Heparin/
#2 heparin.tw
#3 Low Molecular Weight Heparin/
#4 (LMWH OR low molecular weight heparin OR nadroparin OR
fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin
OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logi-
parin OR innohep OR certoparin OR sandoparin OR reviparin OR
clivarin OR danaproid OR orgaran).tw
#5 1 OR 2 OR 3 OR 4
#6 Coumarin derivative/
#7 Warfarin/
#8 (warfarin OR coumadin OR acenocumarol OR phenprocumon
OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K an-
tagonist OR VKA).tw
#9 6 OR 7 OR 8
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#10 fondaparinux/
#11 (fondaparinux OR Arixtra).tw
#12 ximelagatran/
#13 (ximelagatran OR Exanta).tw
#14 (Pradaxa ORDabigatran OR rivaroxaban OR Xarelto OR apix-
aban).tw.
#15 5 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14
#16 Neoplasm/
#17 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR
adenocarcinoma OR tumour OR tumor).tw
#18 16 OR 17
#19 Random:.tw. OR clinical trial:.mp. OR exp health care quality
#20 animals/ NOT human/
#21 19 NOT 20
#22 15 AND 18 AND 21
ISI (International Scientific Information) the Web of Science #1 heparin OR low molecular weight heparin OR LMWHOR low-
molecular-weight-heparin OR nadroparin OR fraxiparin OR enoxa-
parin OR clexane OR lovenox OR dalteparin OR fragmin OR arde-
parin OR normiflo OR tinzaparin OR logiparin OR innohep OR
certoparin OR sandoparin OR reviparin OR clivarin OR danaproid
OR orgaran
#2 Coumarins OR Warfarin OR coumadin OR acenocumarol OR
phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR
vitamin K antagonist OR VKA
#3 fondaparinux OR Arixtra
#4 ximelagatran OR Exanta
# 5 Pradaxa OR Dabigatran OR rivaroxaban OR Xarelto OR apix-
aban
#6 1 OR 2 OR 3 OR 4 OR 5
#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR ade-
nocarcinoma OR tumour OR tumor
#8 random$ OR placebo$ OR versus OR vs OR double blind OR
double-blind OR compar$ OR controlled
#9 6 AND 7 AND 8
CENTRAL (The Cochrane Library, latest issue) #1 heparin OR low molecular weight heparin OR LMWHOR low-
molecular-weight-heparin OR nadroparin OR fraxiparin OR enoxa-
parin OR clexane OR lovenox OR dalteparin OR fragmin OR arde-
parin OR normiflo OR tinzaparin OR logiparin OR innohep OR
certoparin OR sandoparin OR reviparin OR clivarin OR danaproid
OR orgaran
#2 Coumarins OR Warfarin OR coumadin OR acenocumarol OR
phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR
vitamin K antagonist OR VKA
#3 fondaparinux OR Arixtra
#4 ximelagatran OR Exanta
#5 Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban
#6 1 OR 2 OR 3 OR 4 OR 5
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#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR ade-
nocarcinoma OR tumour OR tumor
#8 6 AND 7
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